| 贾晓锋1 梁军1△ 吕红英1 姚如永2 周非1 韩越1.XPA 及XPG 基因多态性与晚期非小细胞肺癌铂类药物化疗疗效及
预后的关系[J].现代生物医学进展英文版,2011,11(9):1718-1722. |
| XPA 及XPG 基因多态性与晚期非小细胞肺癌铂类药物化疗疗效及
预后的关系 |
| Relationship between XPA and XPG polymorphisms and platinum-basedchemotherapy outcomes in advanced non-small cell lung cancer |
| |
| DOI： |
| 中文关键词: 基因，XPA，XPG 多态现象，遗传 肺肿瘤/ 药物疗法 |
| 英文关键词: Genes XPA,XPG Polymorphism,genetic Lung neoplasms/Drug therapy |
| 基金项目:青岛市科技局项目（Kzd-17） |
|
| Hits: 729 |
| Download times: 995 |
| 中文摘要: |
| 目的：研究DNA 修复基因XPA A23G 及XPG C46T 位点基因多态性与晚期非小细胞肺癌铂类化疗疗效及预后的关系。方
法：经病理学确诊的晚期非小细胞肺癌患者89 例，化疗前提取其外周血DNA，用DNA 测序技术检测XPA、XPG 基因型，所有患
者均接受2-4 个周期铂类药物为基础的化疗。结果：1）89 例患者中，携带XPA23A/A 及A/G+G/G 基因型的化疗有效率分别为
47.5 %和24.5 %,差异有统计学意义（x2 =5.137，P=0.023）；携带XPG46C/C 及C/T+T/T 基因型的患者治疗有效率分别为47.6 %、
23.4 %，二者间也有统计学差异（x2 =5.729，P=0.017），联合分析显示A/A 及C/C 型化疗有效率最高，达63.0 %，而A/A 及C/T+T/T
型最低，仅15.4 %，四组间有显著统计学差异（x2 =14.080，P=0.003）。2）89 例患者中位TTP 为7 个月,XPA23A/A 基因型中位TTP
为11 个月,A/G+G/G 基因型为6 个月，两者比较差异有显著性(x2 = 44.640,P<0.01)；XPG46C/C 基因型中位TTP 为10 个月,
C/T+T/T 基因型为6 个月，两者也有统计学差异(x2 = 32.236，P<0.01)。联合分析显示,XPA A/A+XPG C/C 型中位TTP 最长，达到
11 个月，而A/G+G/G 及C/T+T/T 基因型最短，仅有4 个月，四组间差异有显著统计学意义(x2 = 59.295，P<0.01)。结论：XPA A23G
及XPG C46T 单核苷酸多态性可单独及联合用于预测晚期NSCLC 病人对铂类药物的化疗疗效及TTP，初步提示可以根据患者
基因型来指导个体化治疗。 |
| 英文摘要: |
| Objective: To investigate the relationship between XPA, XPG single nucleotide polymorphism(SNP）and chemotherapy
outcomes in advanced non-small cell lung cancer (NSCLC) patients. Methods: 89 NSCLC patients were included who were histologically
diagnosed and staged as clinical stage IIIB or IV.All patients received platinum-based doublets combination chemotherapy. We used
sequencing technology to survey the distribution of XPA and XPG genotypes. Results: 1)The response rate in patients with XPA23A/A
genotype significantly higher than that in patients with 23A/G+G/G genotype（x2 =5.137，P=0.023）,and XPG46C/C genotype higher than
that in patients with 46C/T+T/T genotype （x2 =5.729, P=0.017）.Combined with XPA and XPG，patients with A/A and C/C had a higher
response than that in patients with other genotypes.2）The median TTP was 7 months.11 months for XPA 23A/A genotype, and 6 months
for 23A/G+G/G genotype.The differences among them were significant (x2 = 44.640, P<0.01);also,10 months for XPG 46C/C genotype，
and 6 months for 46C/T+T/T genotype.The differences among them were significant (x2 = 32.236，P<0.01). Combined with XPA and
XPG we can see that patients with A/A and C/C had a higher TTP than patients with other genotypes. Conclusions: Polymorphisms of
XPA and XPG may be correlated with clinical response and TTP to platinum-based chemotherapy. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
